• Medicxi, a major European life sciences VC firm, closed Medicxi V, a €500 million fund focused on building and backing innovative biotech companies.
• The fund was oversubscribed, with strong support from existing LPs and select new institutional investors.
• Medicxi V will continue the firm’s asset-centric investment model, targeting companies with clear product visions that can transform patient care.
• Since its last fundraise, Medicxi has created 16 new companies, delivered over 20 positive clinical data readouts, and realised over $1 billion across its portfolio.
• Notable successes include Vaxcyte, Merus, Abivax, and acquisitions of ViceBio (Sanofi), Versanis Bio (Eli Lilly), and ProfoundBio (Genmab).
• The new fund will support both new company creation and investments in existing companies aligned with Medicxi’s asset-centric strategy.
• Francesco De Rubertis stated that Medicxi’s success is rooted in strong ties to global pharma companies and a world-class team of drug hunters and clinicians.
• Giovanni Mariggi highlighted that Medicxi’s capital-efficient strategy has enabled the firm to raise six funds in 10 years, totalling over €2.0 billion.
• Shyam M. has been promoted to Partner; he led investments in Merus and ProfoundBio and sits on the boards of Acera Therapeutics, T-CypherBio and Petalion Therapeutics.
• The fund was oversubscribed, with strong support from existing LPs and select new institutional investors.
• Medicxi V will continue the firm’s asset-centric investment model, targeting companies with clear product visions that can transform patient care.
• Since its last fundraise, Medicxi has created 16 new companies, delivered over 20 positive clinical data readouts, and realised over $1 billion across its portfolio.
• Notable successes include Vaxcyte, Merus, Abivax, and acquisitions of ViceBio (Sanofi), Versanis Bio (Eli Lilly), and ProfoundBio (Genmab).
• The new fund will support both new company creation and investments in existing companies aligned with Medicxi’s asset-centric strategy.
• Francesco De Rubertis stated that Medicxi’s success is rooted in strong ties to global pharma companies and a world-class team of drug hunters and clinicians.
• Giovanni Mariggi highlighted that Medicxi’s capital-efficient strategy has enabled the firm to raise six funds in 10 years, totalling over €2.0 billion.
• Shyam M. has been promoted to Partner; he led investments in Merus and ProfoundBio and sits on the boards of Acera Therapeutics, T-CypherBio and Petalion Therapeutics.
• Investing Partners for Fund V: Francesco De Rubertis, Giovanni Mariggi, Nick Williams and Shyam Masrani.